Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $10.58
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 8, 26 |
| HC Wainwright & Co. |
| maintain |
| Buy |
| Buy |
| Apr 20, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Feb 13, 26 | HC Wainwright & Co. | upgrade | Neutral | Buy |
| Jun 2, 25 | HC Wainwright & Co. | downgrade | Buy | Neutral |
| Nov 11, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
| Oct 18, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
763 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 35.48 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 7.49 | Oscillator | Buy |
| Williams %R (14) | -95.65 | Oscillator | Buy |
| MACD (12, 26, 9) | -1.17 (Hist -0.35) | Oscillator | Strong Sell |
| Average Directional Index (14) | 26.17 (+DI 12.4 / -DI 26.0) | Trend | Strong Sell |
| EMA 20 | 12.63 | MA | Strong Sell |
| SMA 20 | 13.30 | MA | Strong Sell |
| EMA 50 | 13.41 | MA | Strong Sell |
| SMA 50 | 14.17 | MA | Strong Sell |
| SMA 200 | 11.17 | MA | Strong Sell |
Stock news · updated daily
AN4035, a first-in-class investigational pan-RAS(ON) inhibitor-based ADC, will be evaluated as monotherapy and in combination with cetuximab in the ongoing global Phase I trial
Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Thermo Fisher Scientific (TMO) have performed compared to their sector so far this year.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 14, 2026 | -0.06 | -0.04 | Beat 30.4% | $14.68M |
| Apr 10, 2026 | -0.18 | -0.81 | Miss -350.0% | $2.50M |
| Dec 29, 2025 | -0.18 | -0.18 | Beat 0.0% | — |
| Aug 7, 2025 | -0.18 | -0.18 | Beat 0.0% | — |
| Apr 30, 2025 | -0.53 | -0.22 | Beat 58.5% | — |
| Feb 26, 2025 | -0.53 | -0.22 | Beat 58.5% | — |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 6-K | Oct 15, 2026 | 2026-10-15 07:00:04 | View |
| 4 | Oct 1, 2026 | 2026-10-01 10:04:33 | View |
| 6-K | Sep 30, 2026 | 2026-09-30 08:30:16 | View |
| 6-K | Sep 30, 2026 | 2026-09-30 06:04:05 | View |
| 4 | Sep 24, 2026 | 2026-09-24 11:07:53 | View |
| EFFECT | Sep 15, 2026 | 2026-09-16 00:15:06 | View |
| S-8 POS | Sep 11, 2026 | 2026-09-11 13:22:44 | View |
| S-8 POS | Sep 11, 2026 | 2026-09-11 13:21:26 | View |
| POS AM | Sep 11, 2026 | 2026-09-11 13:19:37 | View |
| 6-K | Sep 8, 2026 | 2026-09-08 08:00:17 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | ANL | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -5.4x | -1.6x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -57.4x | EPS est. -0.18 | Elevated |
| Price / Book | 0.8x | -0.3x | Discount |
| Price / Sales | 28.5x | 1.4x | Elevated |
| EV / EBITDA | -21.7x | -1.1x | Elevated |
| Return on equity | -21.8% | — | Weak |
| Gross margin | 100.0% | 40.0% | Above hist. |
| Debt / Equity | 0.12 | -0.36 | Conservative |
| Piotroski / Altman Z | 3/9 | Z 8.22 | Safe zone |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 29, 26 | Ji Ping | director | S-Sale | 214 @ $15.77 | $3.37K |
| Sep 30, 26 | Ji Ping | director | S-Sale | 5,000 @ $16.03 | $80.15K |
| Sep 30, 26 | Ji Ping | director | S-Sale | 5,000 @ $15.95 | $79.75K |
| Sep 22, 26 | Ji Ping | director | S-Sale | 5,000 @ $16.63 | $83.15K |
| Aug 24, 26 | Ye Xiaofeng | officer: CFO | S-Sale | 6,000 @ $13.98 | $83.88K |
| Aug 26, 26 | Ye Xiaofeng | officer: CFO | S-Sale | 5,667 @ $14.25 | $80.75K |
| Mar 18, 26 | Birgerson Lars Erik | director | 0 | — | |
| Mar 18, 26 | Sawhney Roger | director | 0 | — |